These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19455969)

  • 1. [New therapies for age-related macular degeneration].
    Kachi S; Ishikawa K; Terasaki H
    Nippon Ganka Gakkai Zasshi; 2009 Apr; 113(4):479-91. PubMed ID: 19455969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatments for age-related macular degeneration.
    Imrie FR; Bailey C
    Age Ageing; 2007 Jan; 36(1):8-10. PubMed ID: 17264135
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
    Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
    Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monoclonal antibodies targeting VEGF in ophthalmology: the case of exudative age-related macular degeneration].
    Leveziel N; Soubrane G; Souied EH
    Med Sci (Paris); 2009 Dec; 25(12):1105-7. PubMed ID: 20035686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
    Tamaki Y
    Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of gene therapy for treatment of age-related macular degeneration.
    Askou AL
    Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferred therapies for neovascular age-related macular degeneration.
    Chiang A; Regillo CD
    Curr Opin Ophthalmol; 2011 May; 22(3):199-204. PubMed ID: 21427571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatments for age-related macular degeneration.
    Mittra RA; Ramsay RC
    Minn Med; 2009 Jun; 92(6):41-4. PubMed ID: 19653472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
    Karel I
    Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.
    Dixon JA; Oliver SC; Olson JL; Mandava N
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidance for the treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth UM; Richard G; Augustin A; Aylward WG; Bandello F; Corcòstegui B; Cunha-Vaz J; Gaudric A; Leys A; Schlingemann RO;
    Acta Ophthalmol Scand; 2007 Aug; 85(5):486-94. PubMed ID: 17655610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM; Noureddine BN; Bashshur ZF
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wet age-related macular degeneration.
    Kulkarni AD; Kuppermann BD
    Adv Drug Deliv Rev; 2005 Dec; 57(14):1994-2009. PubMed ID: 16309781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab: a new way of doing business?
    Canning C; Lotery A
    Eye (Lond); 2006 Sep; 20(9):985-7. PubMed ID: 16858443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
    Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia.
    Cohen SY
    Retina; 2009 Sep; 29(8):1062-6. PubMed ID: 19734760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
    Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
    J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.